Market Signal Briefing

, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Stride, Inc. ("Stride" or "the Company") (NYSE: LRN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between October 22, 2024 and October 28, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before January 12, 2026.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Stride inflated its enrollment numbers through the utilization of "ghost students." The Company assigned teach caseloads beyond statutory limits to lower its staffing costs. The Company failed to follow compliance requirements such as background checks. The Company suppressed whistleblower reports on directives to improperly improve profit margins. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Stride, investors suffered damages.

Join the case to recover your losses

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.          

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE The Schall Law Firm

AMSTERDAM--(BUSINESS WIRE)--Prosus N.V. (Prosus) (AEX and JSE: PRX) is delivering on its ecosystem strategy, with strong growth, results and synergies taking hold across Latin America, Europe and India. Disciplined execution is driving our performance, with all of our operated businesses now profitable. We are on track to achieve our guidance1 of US$1.1bn+ in adjusted EBITDA for the full year - and this number does not include our recent acquisitions. New investments, notably Just Eat Takeaway.

SINGAPORE--(BUSINESS WIRE)--Hafnia Limited (“Hafnia”, the “Company”, OSE ticker code: “HAFNI”, NYSE ticker code “HAFN”) will release its Q3 2025 results at approximately 07:30 CET on the 1st of December 2025. In connection with this release, Hafnia will hold an investor presentation with Mikael Skov (CEO), Perry van Echtelt (CFO), Søren Skibdal Winther (VP), and Thomas Andersen (EVP). The details are as follows: Location Local Time Oslo, Norway 14:30 CET New York, U.S.A 08:30 EST Singapore 21:3.

EINDHOVEN, the Netherlands, Nov. 24, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries (SCI) and other movement disabilities, today announced its results for the third quarter of 2025 and provides a comprehensive business update:

Commercial traction: The Company met its objective of 40 ARC-EX® Systems sold in Q3.
Regulatory milestones: The US Food and Drug Administration (FDA) approved an investigational device exemption (IDE) for the ARC-IM® System, allowing the initiation of the Empower BP global pivotal study. The Company received CE Mark certification for the ARC-EX System. In November, the FDA also cleared the ARC-EX System for home use in the US.
Science & technology leadership: Key publications in Nature, Nature Medicine, and Neurology: Clinical Practice added to the strong body of clinical evidence supporting the Company’s innovative therapies.
Financial highlights: The Company reported EUR 1.7 million in revenue in Q3 and successfully raised over EUR 50 million in equity capital in October, extending runway into Q1 2027. Dave Marver, CEO of ONWARD Medical, said: “We continued to deliver strong commercial execution in Q3, and we achieved several meaningful scientific and regulatory milestones across our technology platforms. Home-based ARC-EX Therapy greatly enlarges the US market opportunity and helps fulfill our mission to provide the SCI community with broad and convenient access to innovative therapies. We are also well positioned to initiate Empower BP, our second global pivotal study and the first to evaluate the ARC-IM implanted neuromodulation platform to address blood pressure instability after SCI. The recent well-supported financing allows us to further advance our strategic priorities with focus, discipline and determination.”

Commercial traction

The Company met its objective of 40 ARC-EX Systems sold in Q3, demonstrating continued strong commercial traction for its groundbreaking external spinal cord stimulation technology.

ARC-EX Therapy is now available in over 60 clinics across the US.

Regulatory milestones

The Company received CE Mark certification for the ARC-EX System, allowing commercialization for both clinic and home use in the European Union. The CE Mark facilitates a streamlined regulatory pathway in other countries, including the UK and Switzerland. First commercial sales of the ARC-EX System in Europe are expected in Q4.

In November, the Company received 510(k) clearance to expand the ARC-EX System indication for home use in the US. ARC-EX is the first and only FDA-cleared technology demonstrated to improve hand strength and sensation in people with SCI.

The US FDA also approved an IDE for the ARC-IM System, allowing the initiation of the Empower BP global pivotal study designed to assess the safety and effectiveness of this novel technology designed to manage blood pressure instability in people with SCI. The first patient enrollment in Empower BP is anticipated before the end of the year.

Science & technology leadership

The Company announced the simultaneous publication of two landmark articles in Nature and Nature Medicine. They highlighted advances in blood pressure regulation after SCI and added to the compelling body of scientific and clinical evidence supporting the ARC-IM System ahead of the initiation of Empower BP. Detailed results from clinical feasibility studies show immediate improvement in blood pressure stability and durable reduction of hypotensive symptoms, resulting in improved quality of life.

The results of the LIFT Home Study, published in Neurology: Clinical Practice, showed that continued use of ARC-EX Therapy at home is effective in maintaining and extending gains achieved in the clinic.

Financial highlights

The Company reported EUR 1.7 million in revenue in Q3, exceeding the EUR 1 million mark in quarterly revenue for the first time.

In October, the Company successfully raised over EUR 50 million in equity capital. The transaction was supported by strong demand from existing and new high-quality, long-only, and sector specialist investors. The net proceeds from the transaction are expected to provide the Company with cash runway into Q1 2027, assuming no draw down of the Company’s debt facility. As of October 31, 2025, the cash balance was EUR ​77.7 million.

BNP Paribas’ broker Portzamparc initiated coverage with a Buy rating and Target Price of EUR 10.20, expanding the Company’s equity research coverage to five leading banks, each with Buy ratings.

Outlook

Continued demand for the ARC-EX System and positive feedback from users suggest the Company is on track to deliver a strong first year as a commercial organization. The CE Mark certification and FDA clearance to market the ARC-EX System for home use put the Company in a strong position to accelerate growth in 2026.

The Company anticipates first patient enrollment in the Empower BP pivotal study before the end of the year. It also plans additional implants of its ARC-IM and ARC-BCI® Systems to explore potential future indications, including mobility in SCI and Parkinson’s disease.

Webcast details

ONWARD Medical will hold a webcast today, November 24, 2025, at 2:00 p.m. CET / 8:00 a.m. ET, hosted by CEO Dave Marver. To join the session, please register using this link.

About ONWARD Medical

ONWARD Medical is the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries and other movement disabilities. Building on decades of scientific discovery, preclinical research, and clinical studies conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company developed ARC Therapy. It has subsequently been awarded 10 Breakthrough Device Designations from the FDA. The Company’s ARC-EX® System is cleared for commercial sale in the US and Europe. The Company is also developing an investigational implantable system called ARC-IM®, designed to address several unmet needs, including blood pressure instability after spinal cord injury. It can also be paired with a brain-computer interface (BCI) and artificial intelligence (AI) to restore thought-driven movement.

Headquartered in the Netherlands, the Company has a Science and Engineering Center in Switzerland and a US office in Boston, Massachusetts. The Company is listed on Euronext Paris, Brussels, and Amsterdam (ticker: ONWD) and its US ADRs can be traded on OTCQX (ticker: ONWRY). For more information, please visit ONWD.com.

To stay informed about ONWARD’s research studies, technologies, and the availability of therapies in your area, please complete this webform.

For Media Inquiries:
Sébastien Cros, VP Communications
[email protected]  

For Investor Inquiries:
[email protected]

Forward-Looking Statements  

Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors, including, but not limited to, delays in regulatory approvals, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers nor representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors, nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Trademarks: ONWARD, ARC-EX, ARC-IM, ARC-BCI, and the stylized O-Logo are proprietary and registered trademarks of ONWARD Medical. Unauthorized use is strictly prohibited.

ARC-EX Indication for Use: The ARC-EX System is intended to deliver programmed, transcutaneous electrical spinal cord stimulation in conjunction with functional task practice in the clinic and with take-home exercises in the home to improve hand sensation and strength in individuals between 18 and 75 years old that present with a chronic, nonprogressive neurological deficits resulting from an incomplete spinal cord injury (C2-C8 inclusive). The ARC-EX System is intended to be operated in medical centers by rehabilitation professionals and at home by patients and persons providing assistance to patients, as needed.

Other Investigational Products: All other ONWARD Medical devices and therapies, including ARC-IM and ARC-BCI, are investigational and not available for commercial use.

Neurogene has transitioned into a data-driven, registrational-stage company with NGN-401 showing strong safety and efficacy for Rett syndrome. NGNE's disciplined financial management provides a cash runway through Q1 2028, allowing focused investment in its lead asset and minimizing dilution risk. NGN-401's clinical data demonstrate durable, multi-domain functional gains and a favorable safety profile, positioning it as a potential first-in-class therapy.

, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Primo Brands Corporation ("Primo" or "the Company") (NYSE: PRMB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the publicly traded securities of Primo Water Corporation ("Primo Water") between June 17, 2024 through November 8, 2024, inclusive, and/or (the publicly traded common stock of Primo Brands Corporation between November 11, 2024 through November 6, 2025, are encouraged to contact the firm before January 12, 2026.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Prime failed to disclose material facts about its merger with BlueTriton Brands, including updates on the progress of its integration. The Company led investors to believe the merger would accelerate growth and create operational efficiencies, falsely claiming that the merger was proceeding "flawlessly." Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Primo, investors suffered damages.

Join the case to recover your losses

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.          

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]

SOURCE The Schall Law Firm

Grayscale is scheduled to bring its spot XRP and Dogecoin ETFs to market tomorrow.

Key Takeaways

Franklin Templeton’s XRP ETF has secured approval for listing on NYSE Arca.
The fund will trade under XRPZ and feature a 0.19% NAV-based sponsor fee.

NYSE Arca has approved the listing of Franklin Templeton’s XRP ETF and formally certified the action to the SEC. It means the fund has met all exchange requirements and is nearing launch.

Per Franklin’s latest disclosure, the ETF, the Franklin XRP Trust, will list under the ticker XRPZ and impose an annual sponsor fee of 0.19% of net asset value. The sponsor plans to waive the fee entirely on the initial $5 billion in assets through May 31, 2026.

Franklin will soon join a number of fund managers in bringing a regulated investment product tied to XRP to the US market. Canary Capital and Bitwise Asset Management rolled out their spot XRP ETFs earlier this month.

Grayscale is poised to launch its spot XRP and Dogecoin ETFs tomorrow after securing final clearance.

XRP was trading at over $2 at press time, up almost 3% in the last 24 hours, CoinGecko data shows.

Disclaimer

Forward Industries holds 6,910,568 SOL tokens valued at $917.42 million, down from a $1.59 billion acquisition cost, resulting in unrealized losses of $668.73 million.Approximately 79.6% of Solana's circulating supply is currently held at a loss at $126.9, reflecting widespread pain across the SOL market after its decline from November 2024 highs.Forward Industries' recent transfer of 1.727 million SOL to a custody wallet was subsequently moved back to staking, indicating portfolio restructuring rather than capitulation.Forward Industries, the largest institutional holder of Solana with more than 1.1% of the total supply, currently faces unrealized losses of $668 million. SOL’s price drop has left nearly 80% of its circulating supply underwater, highlighting significant risks for Digital Asset Treasury companies.

This sharp reversal underscores the mounting pressure on institutional crypto strategies amid worsening market conditions.

Sponsored

Forward Industries’ Massive SOL Position Faces Heavy LossesForward Industries (NASDAQ: FWDI) holds 6,910,568 SOL, totaling roughly 1.124% of Solana’s circulating supply. CoinGecko data shows the company’s SOL treasury is now worth $917.42 million, down from a $1.59 billion acquisition cost. Its average purchase price of $230 per SOL has resulted in an unrealized loss of $668.73 million, or 42.2%.

The company initiated its Solana treasury strategy in September 2025. According to an official BusinessWire release, Forward Industries initially bought 6,822,000 SOL at around $232 per token, for a total investment of $1.58 billion. Its holdings have grown slightly, with the latest disclosure on November 15, 2025, confirming 6,910,568 SOL in its treasury.

Source: BeInCryptoThe company’s stock price has dropped alongside its crypto assets, falling from a high of $40 to $8.17. Billions in shareholder value have been erased. Today, Forward Industries’ market capitalization is $706.38 million—less than the value of its SOL holdings.

Sponsored

SOL Market Structure Reveals Widespread PainThese losses are part of a larger market decline. Glassnode data reveals that about 79.6% of SOL’s circulating supply—approximately 478.5 million tokens—is now held at a loss at a price of $126.9. This figure underscores how top-heavy the market had become before the current downturn.

Many investors and institutions joined the SOL rally in late 2024 and early 2025. Solana’s all-time high was $263.2 in November 2024, according to Oak Research, with a 41.4% gain that month. However, the token has since retraced by more than 50% from its peak.

This turn comes despite Solana showing strong fundamentals. In November 2024, Solana overtook Ethereum in monthly fee revenue for the first time, with fees rising 171% to about $200.69 million. The total value locked increased by 73% to $11.4 billion, making Solana the world’s second-largest blockchain by TVL.

The percent of SOL supply in profit plunges as the price contracts from its highs. Source: GlassnodeSponsored

Portfolio Movement Sparks SpeculationRecent blockchain activity has raised questions about Forward Industries’ approach. The company executed a significant Solana transaction, transferring 1.727 million SOL, valued at around $219.32 million, to the wallet address 552ptg. However, these funds soon returned to the company’s staking account, suggesting no sell-off occurred.

Market watchers saw this as portfolio restructuring, not capitulation. The company continues to stake its SOL, generating yield while retaining its position. Although it added 38,968 SOL last month, Forward Industries has not significantly changed its treasury strategy.

Forward Industries’ 1.727M SOL transfer to custody wallet showing portfolio management activity. BeInCryptoSponsored

Forward Industries’ situation differs sharply from other Digital Asset Treasury companies. Market data shows Strategy’s 649,870 BTC, purchased at an average of $74,433, has an unrealized profit of $6.15 billion—a gain of 12.72%. Meanwhile, Bitmine’s 3,559,879 ETH, bought at roughly $4,010 each, carries an unrealized loss of $4.52 billion, or 31.67%.

This divergence highlights the volatility Digital Asset Treasury companies can face. Galaxy research indicates that DATCOs hold over $100 billion in digital assets, with bitcoin-focused companies holding $93 billion and ETH-focused firms over $4 billion. On the other hand, however, these companies can amplify volatility due to their significant, sometimes leveraged, exposures.

Market Dynamics and Future OutlookOpen interest in Solana futures has stabilized around 8 million contracts after periods of volatility. This suggests a consolidation phase. When open interest is steady and prices are falling, it often signals lower conviction and possible liquidations. As a result, traders appear cautious, awaiting potential catalysts for a rebound.

Forward Industries, led by Chairman Kyle Samani and based in the United States, remains committed to its Solana treasury strategy despite heavy losses. The company’s future hinges on Solana’s ability to recover and establish new support.

Disclaimer

In adherence to the Trust Project guidelines, BeInCrypto is committed to unbiased, transparent reporting. This news article aims to provide accurate, timely information. However, readers are advised to verify facts independently and consult with a professional before making any decisions based on this content. Please note that our Terms and Conditions, Privacy Policy, and Disclaimers have been updated.

1 hour ago

Jan van Eck says quantum computing could threaten Bitcoin's encryption and privacy, and his firm “will walk away” if it’s “fundamentally broken.”

682

Bitcoin’s encryption and privacy could be at risk from quantum computing, but it is still a good investment for now, says Jan van Eck, CEO of investment manager VanEck.

“There is something else going on within the Bitcoin community that non-crypto people need to know about,” van Eck told CNBC on Saturday. “The Bitcoin community has been asking itself: Is there enough encryption in Bitcoin? Because quantum computing is coming.”

He said that the company believes in Bitcoin (BTC), but it was around before the cryptocurrency launched and “will walk away from Bitcoin if we think the thesis is fundamentally broken.”

VanEck is one of the world’s largest crypto asset managers and has multiple Bitcoin products, including a spot Bitcoin exchange-traded fund in the US that has taken in over $1.2 billion in inflows since launching in early 2024.

Jan van Eck speaking on the quantum computing risk. Source: CNBCBitcoiners eye Zcash for more privacy Van Eck said that a lot of Bitcoin “OGs or maxis” have been looking at Zcash (ZEC), a privacy-focused token, in their search for more privacy for their transactions.

Zcash has soared by over 1,300% in the past three months as the market has rushed to embrace privacy tokens amid a renewed surge in interest for anonymous crypto transactions.

Cryptographer and cypherpunk Adam Back said earlier this month that Bitcoin is unlikely to face a meaningful threat from quantum computing for at least two to four decades.

Bear market being priced inVan Eck concluded that the four-year cycle is being priced in right now, recommending dollar-cost averaging into bear markets rather than chasing bull markets.

He said Bitcoin “for sure” needs to be included in investor portfolios due to “mainstream global liquidity reasons,” and the “onchain reality.” 

He briefly explained that halving cycle, adding that every four years over the past decade, Bitcoin has had a big negative year, “and in 2026 it’s scheduled to have a big negative year,” and investors have been pre-positioning for this bearish move. 

“Every cycle is different. What’s obvious to everybody is that Bitcoin has gone up less this cycle, and so many people think it will go down less in the correction.”

Bitcoin has lost more than 30% since its early October all-time high, bottoming out at just over $82,000 on Friday before recovering to tap $88,000 in early trading on Monday. 

Magazine: Bitcoin $200K soon or 2029? Scott Bessent hangs at Bitcoin bar: Hodler’s Digest

Eric Trump, co-founder of American Bitcoin Corp. (NASDAQ:ABTC), reiterated his bullish stance on Bitcoin (CRYPTO: BTC) in an interview aired Saturday, encouraging investors to buy the current market dip.

Trump Urges To Buy The DipDuring an interview with CNBC, Trump was asked whether he planned to capitalize on the ongoing slump to add more BTC to his company’s reserves.

“This is a great time to buy Bitcoin. There’s no question,” Trump responded.

Trump, also the executive vice president of the Trump Organization, spoke on how people rue that Bitcoin is expensive all the time, and when it drops, they’re unsure whether to buy it.

See Also: Bitcoin (BTC) Price Predictions: 2025, 2026, 2030

“Bitcoin has been the greatest asset of our time,” Trump said, highlighting its “unbelievable” returns over the last decade.

He repeated his belief that Bitcoin would eventually hit a million dollars apiece, though it’ll take “some years” to do so.

Trump’s ‘Unbelievable’ Q4Trump’s bullish stance on Bitcoin and cryptocurrency is not new, with his personal experiences with debanking serving as a major factor.

Interestingly, Trump had projected that the fourth quarter would be “unbelievable” for the cryptocurrency market. Now, midway through the quarter, things haven’t unfolded quite as he expected, with Bitcoin down 23%, a sharp reversal from the 47% gains it made in the same quarter last year.

Trump’s company, American Bitcoin, currently holds 4,004 BTC, worth $350 million, according to BitcoinTreasuries.net.

Price Action: At the time of writing, BTC was exchanging hands at $87,344.15, up 1.49% in the last 24 hours, according to data from Benzinga Pro.

American Bitcoin shares closed 3.28% lower at $4.430 during Friday’s regular trading session, according to data from Benzinga Pro.

According to Benzinga’s Edge Stock Rankings, the stock lagged on the Value metric and was in a downward trend in the short, medium, and long term. Find out more here.

Read Next: 

Bitcoin, Ethereum, XRP, Dogecoin Rebound After Steep Sell-Off: Analyst Highlights ‘Good Bounce’ For BTC, Predicts Level Before A ‘New Base’ Is Found
Disclaimer: This content was partially produced with the help of Benzinga Neuro and was reviewed and published by Benzinga editors.

Photo Courtesy: Maxim Elramsisy On Shutterstock.com

Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

XRP price started a fresh decline below $2.00. The price is now recovering from $1.820 and might face hurdles near the $2.150 pivot level.

XRP price started a recovery wave from the $1.820 zone.
The price is now trading above $2.00 and the 100-hourly Simple Moving Average.
There was a break above a key bearish trend line with resistance at $2.00 on the hourly chart of the XRP/USD pair (data source from Kraken).
The pair could continue to move up if it settles above $2.150.

XRP Price Eyes Recovery
XRP price extended losses below the $2.00 support, like Bitcoin and Ethereum. The price even spiked below $1.90 before the bulls appeared. A low was formed at $1.8177, and the price is now attempting to recover.

There was a move above the $1.88 and $1.95 levels. The bulls were able to push the price above the 50% Fib retracement level of the downward move from the $2.140 swing high to the $1.817 low. Besides, there was a break above a key bearish trend line with resistance at $2.00 on the hourly chart of the XRP/USD pair.

The price is now trading above $2.00 and the 100-hourly Simple Moving Average. It is also above the 76.4% Fib retracement level of the downward move from the $2.140 swing high to the $1.817 low.

Source: XRPUSD on TradingView.com
If there is a fresh upward move, the price might face resistance near the $2.120 level. The first major resistance is near the $2.150 level. A close above $2.150 could send the price to $2.20. The next hurdle sits at $2.250. A clear move above the $2.250 resistance might send the price toward the $2.320 resistance. Any more gains might send the price toward the $2.350 resistance. The next major hurdle for the bulls might be near $2.40.

Another Decline?
If XRP fails to clear the $2.150 resistance zone, it could start a fresh decline. Initial support on the downside is near the $2.00 level. The next major support is near the $1.980 level.

If there is a downside break and a close below the $1.980 level, the price might continue to decline toward $1.880. The next major support sits near the $1.8450 zone, below which the price could continue lower toward $1.80.

Technical Indicators

Hourly MACD – The MACD for XRP/USD is now gaining pace in the bullish zone.

Hourly RSI (Relative Strength Index) – The RSI for XRP/USD is now above the 50 level.

Major Support Levels – $1.980 and $1.880.

Major Resistance Levels – $2.150 and $2.250.

Why Trust CoinGape

CoinGape has covered the cryptocurrency industry since 2017,
aiming to provide informative insights to our readers. Our journal analysts bring years of experience in market analysis and blockchain technology to ensure factual accuracy and balanced reporting. By following our Editorial Policy,
our writers verify every source, fact-check each story, rely on reputable sources, and attribute quotes and media correctly. We also follow a
rigorous Review Methodology when evaluating exchanges and tools. From emerging
blockchain projects and coin launches to industry events and technical developments, we cover
all facets of the digital asset space with unwavering commitment to timely, relevant information.

Dogecoin is set to see a big week in the market as Grayscale readies the launch of its DOGE ETF product later today. This comes after the NYSE approved the fund for trading last Friday.

Grayscale’s DOGE ETF Makes NYSE Debut Today
Grayscale confirmed its Dogecoin fund would start trading on the New York Stock Exchange today. This was after formal approval from the exchange last week. They also recognized all filings submitted to the SEC.

Grayscale Dogecoin Trust ETF (Ticker: $GDOG) offers investors direct exposure to $DOGE. $GDOG starts trading on @NYSE Arca tomorrow. pic.twitter.com/AJUFAnY4K1

— Grayscale (@Grayscale) November 24, 2025

Earlier last week, Bloomberg analyst Eric Balchunas projected a November 24 launch date. This was based on the asset manager’s progress and the NYSE’s advancing approvals.

That prediction proved correct. Balchunas posted images of the NYSE’s approval documents. He said the DOGE ETF was cleared to go live. He also showed that the firm’s Chainlink-based ETF is likely to follow next week.

“Grayscale Dogecoin ETF $GDOG approved to list on NYSE, set to start trading Monday. Their XRP spot is also going live on Monday. $GLNK coming soon too, week after I think,” he said.

According to Balchunas, GDOG could generate first-day volume near $11 million. This projection is based on the activity seen in other newly launched crypto ETFs.

The asset manager shared that the DOGE fund will turn its existing Dogecoin trust into an exchange-traded product that tracks the price of the coin. This change allows the company to use the token’s reserves. This provides investors with a regulated way to invest in the meme coin without needing to manage their own wallets.

Grayscale’s XRP ETF Joins the Line-Up
The GXRP fund is also launching along with GDOG today. Its arrival comes a week after the Bitwise XRP ETF hit the market. The spot fund brought in close to $22 million in trading volume in mere hours following its launch last week. 

Grayscale XRP Trust ETF (Ticker: $GXRP) offers investors direct exposure to $XRP. $GXRP starts trading on @NYSE Arca tomorrow. pic.twitter.com/zee3aMbsAx

— Grayscale (@Grayscale) November 24, 2025

Bloomberg analyst James Seyffart also pointed out that a significant portion of the volume occurred well before the halfway point of the session.

These launches come just on the heels of Canary Capital’s hugely successful debut for its XRPC ETF early this month. The fund saw more than $250 million in inflows on day one.  Since then, firms including 21Shares and CoinShares are also working on their XRP products. 

Meanwhile, in other developments for Dogecoin, 21Shares DOGE ETF saw an update in its key details last month. Although the firm is still waiting for a decision from the SEC. The company plans to list this product on Nasdaq and may join Grayscale in launching its product soon.

Members of the crypto community warn that JPMorgan could face a retail-driven pushback similar to the 2021 GameStop short squeeze.

Photo: Shubham Dhage

Key Takeaways

Grant Cardone and Bitcoin advocates are urging a boycott of JPMorgan after the bank warned of major outflows from Strategy if removed from MSCI indices.
JPMorgan faces criticism for its financial ties to Epstein and alleged shorting of MSTR, increasing scrutiny from the crypto community.

Prominent real estate investor Grant Cardone has joined crypto community members calling for a boycott of JPMorgan after the banking giant warned that Strategy could face up to $2.8 billion in outflows if it is removed from MSCI indices.

If additional index providers follow MSCI’s lead, total withdrawals could reach $8.8 billion, JPMorgan analysts said in a note this week.

In the wake of JPMorgan’s estimates, Strategy stock (MSTR) fell below $200 on Wednesday, according to Yahoo Finance data.

Shares continued to slide through the end of the week, hitting this year’s low of around $170 at Friday’s market close.

The stock had previously peaked at above $450 in mid-July. Year-to-date, MSTR, once outperforming much of the S&P 500, has now logged a 41% decline, and over the past year, it has fallen roughly 57%.

Bitcoin supporters and crypto community members argue that JPMorgan launched a deliberate, premeditated attack on MSTR shareholders.

The accusations come from figures such as Cardone, Max Keiser, an early and outspoken Bitcoin proponent who serves as a senior advisor to President Nayib Bukele, and pro-XRP lawyer John Deaton.

JUST IN: Large numbers of users are allegedly rushing to close accounts at JP Morgan following a premeditated attack on $MSTR shareholders. pic.twitter.com/396wK1ToGi

— The ₿itcoin Therapist (@TheBTCTherapist) November 23, 2025

I cancelled my JPM account and moved entire account to Wells. Also, don’t use chase credit card if you’re worried about fraud. More to come. pic.twitter.com/wi645YqdII

— Grant Cardone (@GrantCardone) November 23, 2025

There are also claims circulating in the market that JPMorgan is shorting MSTR.

Critics have highlighted JPMorgan’s alleged ties to Jeffrey Epstein. The bank has faced Congressional scrutiny and subpoenas regarding its oversight of Epstein’s accounts and financial activities.

Are GameStop vibes returning?As the backlash intensifies, some in the crypto community have warned that their frustration with JPMorgan could grow into a GameStop-style response.

Deaton stated that if retail traders believe that the bank is betting against MSTR, they may rally around the stock as they did with GME and attempt to drive its price higher.

“If @jpmorgan, the financier of Epstein Island and the Lolita Express, whose executives (eg, Jes Staley) participated in raping children, is short @saylor and $MSTR – I hope a GameStop rage trade occurs and costs JPM billions,” Deaton wrote on X.

Disclaimer

Published
20 seconds ago on
November 24, 2025

The New York Stock Exchange has certified the listing and registration for the Grayscale Dogecoin Trust ETF Shares and Grayscale XRP Trust Shares ETF. Both funds will begin trading on NYSE Arca on Monday. 

Grayscale’s two offerings represent conversions from private placement trusts into publicly traded exchange-traded funds.

Grayscale Adds to Its ETF Roster Grayscale, the world’s largest digital-asset focused investment platform, is expanding its lineup of exchange-traded funds (ETFs). On Friday, the platform received word that NYSE Arca, a subsidiary of the NYSE Group, had certified the listings for its spot XRP and DOGE spot ETFs. With this approval, the Grayscale XRP Trust ETF Shares and the Grayscale Dogecoin ETF Shares are cleared to begin public trading. 

Both ETFs will go live on NYSE Arca on Monday, 24 November 2025, and will trade under the tickers $GDOG and $GXRP, respectively. 

The announcement, published on an SEC page, reads:

“The NYSE Arca certifies its approval for listing and registration of the Grayscale XRP Trust ETF Shares, a series of Grayscale XRP Trust ETF, under the Exchange Act of 1934.”

Grayscale’s latest crypto ETFs offer U.S investors easy access to DOGE and XRP, adding to the company’s growing suite of products that track Bitcoin (BTC), Solana (SOL), Dogecoin (DOGE), and Ethereum (ETH).

Both listings are direct conversions from Grayscale’s existing private-placement trusts into publicly traded products. 

Bloomberg senior ETF analyst Eric Balchunas, shared the screenshot of $GDOG’s approval on X and confirmed $GXRP’s approval in the same post. He also hinted that $GLINK, Grayscale’s Chainlink (LINK) ETF, may launch the following week. 

Grayscale Dogecoin ETF $GDOG approved for listing on NYSE, scheduled to begin trading Monday. Their XRP spot is also launching on Monday. $GLNK coming soon as well, week after I think pic.twitter.com/c6nKUeDrtI

— Eric Balchunas (@EricBalchunas) November 21, 2025Spot ETF Approvals Surge in the U.S. Since the SEC approved the first U.S. spot Bitcoin (BTC) ETFs in January 2024, the number of spot ETFs has surged. Spot crypto ETFs exchange-traded products (ETPs) that mirror the real-time price of an underlying digital asset. They acquire cryptocurrencies from authorised crypto exchanges or other holders and secure them in digital wallets - often cold, offline storage to reduce hacking risks. ETFs then issue shares that correspond to the number of tokens they hold and sell shares on traditional stock exchanges, prices reflecting the prevailing market price of the underlying crypto.  

Spot crypto ETFs appeal to retail investors who want exposure to cryptocurrency price movements without the risks and complexities of directly purchasing and safeguarding digital assets. Instead of using crypto exchanges and managing private keys, investors can buy ETF shares through traditional brokerages and gain regulated exposure to the asset. 

Spot ETFs have significantly boosted mainstream crypto adoption by offering convenience, regulatory oversight, market accessibility and potential tax benefits.  

Disclaimer: This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

Bitcoin ETFs, Led By BlackRock's IBIT, See Record $40B Trading Volume as Institutions CapitulateThe U.S.-listed spot bitcoin ETFs saw a record $40 billion in trading volume last week, with IBIT leading the way. Nov 24, 2025, 5:26 a.m.

The 11 U.S.-listed spot bitcoin ETFs shattered trading records last week, with cumulative volumes surpassing $40.32 billion, indicating likely institutional capitulation.

BlackRock's IBIT led the industry with $27.79 billion in trading volume, accounting for nearly 70% of the total, according to data source SoSoValue.

STORY CONTINUES BELOW

On Friday alone, these funds recorded over $11.01 billion in trading volume, with BlackRock's IBIT contributing $8 billion.

The record-setting activity comes hand-in-hand with a plunge in bitcoin's price and large redemptions, pointing to institutional capitulation – the rush by investors to exit the fading bets.

Bitcoin's price has dropped 23% this month to $86,700, falling to nearly $80,000 on some exchanges last week. BlackRock's IBIT has also fallen to its lowest level since April.

BTC's price slide has pushed most ETF holders underwater, as the weighted-average entry price for holders is above $90K, according to Bianco Research.

It's no surprise that the 11 ETFs have cumulatively processed record redemptions worth $3.55 billion this month.

The record redemptions challenge the prevailing belief that these entities take long-term positions, suggesting a possibility that fears of an impending macroeconomic blowup are driving this capitulation.

AI Disclaimer: Parts of this article were generated with the assistance from AI tools and reviewed by our editorial team to ensure accuracy and adherence to our standards. For more information, see CoinDesk's full AI Policy.

More For You

Protocol Research: GoPlus Security

Nov 14, 2025

What to know:

As of October 2025, GoPlus has generated $4.7M in total revenue across its product lines. The GoPlus App is the primary revenue driver, contributing $2.5M (approx. 53%), followed by the SafeToken Protocol at $1.7M.GoPlus Intelligence's Token Security API averaged 717 million monthly calls year-to-date in 2025 , with a peak of nearly 1 billion calls in February 2025. Total blockchain-level requests, including transaction simulations, averaged an additional 350 million per month.Since its January 2025 launch , the $GPS token has registered over $5B in total spot volume and $10B in derivatives volume in 2025. Monthly spot volume peaked in March 2025 at over $1.1B , while derivatives volume peaked the same month at over $4B.View Full Report

More For You

DOGE Beats the Blue Chips as D.O.G.E Calls it Quits

2 minutes ago

DOGE – the memecoin – edged past the CoinDesk 20 and the CoinDesk memecoin index as the White House announced Elon Musk's government efficiency initiative is to shutter.

What to know:

Dogecoin rose over 3% as traders anticipated the launch of Grayscale's DOGE coin ETF.Grayscale's DOGE ETF, trading under the ticker $GDOG, is set to begin trading on NYSE Arca.Cat-themed memecoins outperformed dog-themed coins, with a 4.2% market cap increase compared to 4% for dog-themed coins.Read full story

DOGE – the memecoin – edged past the CoinDesk 20 and the CoinDesk memecoin index as the White House announced Elon Musk's government efficiency initiative is to shutter.Updated Nov 24, 2025, 5:32 a.m. Published Nov 24, 2025, 5:31 a.m.

DOGE$0.1480 looked past the demise of Elon Musk's D.O.G.E. department, as it climbed Monday in Asian markets, driven by renewed optimism sparked by Grayscale’s forthcoming introduction of a DOGE coin ETF.

Loading...

STORY CONTINUES BELOW

CoinDesk market data shows that DOGE was trading around $0.145 on Monday, with a daily gain of over 3%, outpacing the roughly 0.6% rise in the CoinDesk 20 Index (CD20) and the CoinDesk Memecoin Index.

(CoinDesk)

DOGE is rallying into a wave of newly approved spot ETFs, with Grayscale’s GDOG set to begin trading and Bitwise’s rival DOGE product potentially going live under the 20-day 8(a) window, creating a rare bullish catalyst even as whale selling and weak technicals keep near-term price action fragile.

At the same time, BTC and ETH remain sharply lower on a weekly basis with declines of about 9% and 10% while most large cap tokens continue to lag.

While DOGE’s gains are easily attributable to the upcoming ETF launch, typically the token also moves when it finds itself in the headlines – usually from an Elon Musk mention.

The White House confirmed that the Department of Government Efficiency has effectively dissolved eight months ahead of schedule after Elon Musk’s split with President Trump triggered infighting and a quiet transfer of its functions to traditional agencies.

But, despite the usual D.O.G.E-mention, DOGE gain flywheel effect, it's actually cat-themed tokens that have edged ahead.

CoinGecko data shows felines were the actual winner, with the category of cat-themed memecoins growing its market cap by 4.2%, while dog-themed coins are up by 4%.

More For You

Protocol Research: GoPlus Security

Nov 14, 2025

What to know:

As of October 2025, GoPlus has generated $4.7M in total revenue across its product lines. The GoPlus App is the primary revenue driver, contributing $2.5M (approx. 53%), followed by the SafeToken Protocol at $1.7M.GoPlus Intelligence's Token Security API averaged 717 million monthly calls year-to-date in 2025 , with a peak of nearly 1 billion calls in February 2025. Total blockchain-level requests, including transaction simulations, averaged an additional 350 million per month.Since its January 2025 launch , the $GPS token has registered over $5B in total spot volume and $10B in derivatives volume in 2025. Monthly spot volume peaked in March 2025 at over $1.1B , while derivatives volume peaked the same month at over $4B.View Full Report

More For You

Bitcoin ETFs, Led By BlackRock's IBIT, See Record $40B Trading Volume as Institutions Capitulate

7 minutes ago

The U.S.-listed spot bitcoin ETFs saw a record $40 billion in trading volume last week, with IBIT leading the way.

What to know:

The U.S.-listed spot bitcoin ETFs saw a record $40 billion in trading volume last week, with IBIT leading the way. The surge in trading volume, along with price plunge and record redemptions, suggests institutional capitulation. Read full story

Grayscale’s Dogecoin and XRP exchange-traded funds have been cleared for listing on the New York Stock Exchange and are expected to debut later today.

Summary

NYSE Arca secured regulatory signoff to list Grayscale’s new XRP (GXRP) and Dogecoin spot ETFs (GDOGE).
ETF analyst Eric Balchunas expects GDOG to generate trading volumes of around $11 million on its first day.

NYSE Arca, a subsidiary of the exchange, filed and disclosed two separate certifications with the Securities and Exchange Commission on November 21 to confirm its “approval for listing and registration” of the Grayscale XRP Trust ETF Shares (GXRP) and the Grayscale Dogecoin Trust ETF Shares (GDOG).

For those unaware, Grayscale’s GXRP fund will offer direct exposure to the price of XRP, while GDOG tracks the spot price of Dogecoin. Through this structure, investors are able to gain regulated access to these cryptocurrencies without having to hold the underlying assets themselves. Both ETFs operate as spot products, meaning they hold actual XRP and DOGE in custody.

Market analysts, meanwhile, are already setting expectations for the next wave of altcoin ETF listings, and according to Bloomberg’s ETF analyst Eric Balchunas, Grayscale’s Chainlink ETF may be next in line.

“GLNK coming soon as well, week after I think,” Balchunas wrote in a Sunday X post about today’s launch.

Responding to one of his followers regarding his expectations for how these funds may perform on day one, Balchunas said he expects multi-million dollar trading volumes for GDOG.

“Initial guess maybe $11 million. But will ponder more,” he said.

Altcoins ETFs impress at launch
Over the past few weeks, a number of altcoin-focused ETFs, including those tied to XRP, Solana, Litecoin, and HBAR, have surfaced thanks to updated SEC legislation that fast-tracked approvals, which were once delayed by procedural red tape.

Late last month, Bitwise launched its Solana ETF, which began trading alongside Canary Capital’s Litecoin and HBAR funds. In the weeks since, new filings and launches from issuers like Franklin Templeton, 21Shares, and Bitwise have rapidly entered the market.

Most of these ETFs have witnessed solid day-one numbers, with Bitwise’s Solana fund posting nearly $70 million in net inflows at the launch day close, while Canary’s XRP ETF recorded over $250 million when first-day trading ended.

For Grayscale’s GXRP and GDOG ETFs, however, the launch day may be more muted, as the overall crypto market remains in peril. Bitcoin continues to sink below multi-month lows and is giving back most of the gains it posted earlier in the year.

As previously reported by crypto.news, ETF funds from Grayscale and BlackRock have led the recent wave of outflows, as investors continue to pull out funds in what appears to be widespread year-end profit taking and risk-off repositioning.

Recorded the highest number of container ship orders in 18 years since the shipbuilding supercycle in 2007
Signed large-scale supply contract with HMM: HD Hyundai Heavy Industries and HD Hyundai Samho to deliver consecutively through 2029
"Based on our technological competitiveness in eco-friendly and high-efficiency vessels, we will lead the decarbonization of the shipbuilding and shipping industries"
, /PRNewswire/ -- HD Hyundai has secured an order for ultra-large container ships worth around 1.46 billion USD, recording the largest container ship order volume in 18 years since the shipbuilding supercycle in 2007.

HD Korea Shipbuilding & Offshore Engineering (HD KSOE), the intermediate holding company for HD Hyundai's shipbuilding business, announced on Sunday, November 23, that it has signed a shipbuilding contract with HMM for eight 13,400-TEU dual-fuel container ships. The total contract value amounts to 1.456 billion USD.

A 13,000 TEU-class container ship built by HD Hyundai Heavy Industries and delivered in 2024

The vessels ordered are 337 meters in length, 51 meters in width, and 27.9 meters in height. They are equipped with LNG dual-fuel engines and a significantly enlarged fuel tank—expanded by approximately 50%—to enhance operational efficiency. Of the eight vessels, two will be built by HD Hyundai Heavy Industries (HHI) and six by HD Hyundai Samho, with deliveries scheduled consecutively through the first half of 2029.

Through this contract, HD Hyundai has achieved its largest container-ship order volume since 2007, when global cargo demand peaked during the economic boom (793,473 TEU). HD KSOE has secured orders for a total of 720,000 TEU (69 vessels) in container ships this year, marking the highest order volume among domestic shipbuilders.

Container ships built by HD Hyundai are regarded as highly cost-competitive when considering operating expenses over the vessel's entire lifecycle, despite their relatively higher prices compared to competitors.

Since 2023, HD Hyundai has applied "HiNAS Control"—an autonomous navigation assistance system developed by Avikus, a subsidiary specializing in autonomous navigation—to newly built vessels. Actual operational data has confirmed that the system's autonomous navigation support features and RPM optimization deliver a 15% reduction in carbon emissions and a 15% improvement in fuel efficiency.

An HD Hyundai representative stated, "We are further solidifying our position in the global market based on advanced technological capabilities and customer trust," adding, "Going forward, we will continue to lead the decarbonization of the shipbuilding and shipping industries through technological competitiveness focused on eco-friendly and high-efficiency vessels."

SOURCE HD Hyundai

November 23, 2025 10:00 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - November 23, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Molina Healthcare, Inc. (NYSE: MOH) between February 5, 2025 and July 23, 2025, both dates inclusive (the "Class Period"), of the important December 2, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Molina securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Molina class action, go to https://rosenlegal.com/submit-form/?case_id=45913 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 2, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period failed to disclose to investors: (1) material, adverse facts concerning Molina's "medical cost trend assumptions;" (2) that Molina was experiencing a "dislocation between premium rates and medical cost trend;" (3) that Molina's near term growth was dependent on a lack of "utilization of behavioral health, pharmacy, and inpatient and outpatient services;" (4) as a result of the foregoing, Molina's financial guidance for fiscal year 2025 was substantially likely to be cut; and (5) as a result of the foregoing, defendants' positive statements about Molina's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Molina class action, go to https://rosenlegal.com/submit-form/?case_id=45913 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/275529

Analyst’s Disclosure:I/we have a beneficial long position in the shares of XP either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

The author is not an investment advisor and offers no advice here. He shares his own analysis solely for the interest of readers.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

November 23, 2025 10:48 PM EST | Source: The Rosen Law Firm PA
New York, New York--(Newsfile Corp. - November 23, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares ("ADS" or "ADSs") of WPP plc (NYSE: WPP) between February 27, 2025 and July 8, 2025, both dates inclusive (the "Class Period"), of the important December 8, 2025 lead plaintiff deadline.

SO WHAT: If you purchased WPP ADSs during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the WPP class action, go to https://rosenlegal.com/submit-form/?case_id=46121 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 8, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of WPP's media arm; notably, that it was not truly equipped to handle the ongoing macroeconomic challenges while competing effectively and had instead begun to lose significant market share to its competitors. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the WPP class action, go to https://rosenlegal.com/submit-form/?case_id=46121 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/275538